Inequities in cancer drug development in terms of unmet medical need
- 14 April 2022
- journal article
- research article
- Published by Elsevier in Social Science & Medicine
- Vol. 302, 114953
Abstract
No abstract availableKeywords
All Related Versions
This publication has 25 references indexed in Scilit:
- Use of data from registered clinical trials to identify gaps in health research and developmentBulletin of the World Health Organization, 2013
- Innovation and the Burden of Disease: Retrospective Observational Study of New and Emerging Health Technologies Reported by the EuroScan Network from 2000 to 2009Value in Health, 2012
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012
- The productivity crisis in pharmaceutical R&DNature Reviews Drug Discovery, 2011
- Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?BMC Health Services Research, 2011
- Does the development of new medicinal products in the European Union address global and regional health concerns?Population Health Metrics, 2010
- Pharmaceutical Innovation and the Burden of Disease in Developing and Developed CountriesThe Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine, 2005
- Medicare’s National Coverage Decisions, 1999–2003: Quality Of Evidence And Review TimesHealth Affairs, 2005
- Ethics of Phase 1 Oncology StudiesJAMA, 2003
- Factors that influence the recruitment of patients to Phase III studies in oncologyCancer, 2002